JEPT #224386

Introduction
Tubulointerstitial fibrosis is a common event for the progression of chronic kidney disease (CKD) regardless of the primary causes of renal disease (Tampe and Zeisberg, 2014) . Renal fibrogenesis is characterized by activation of renal interstitial fibroblasts and subsequential production of excessive amount of extracellular matrix proteins. The transformation of fibroblasts into myofibroblasts is a core event for the development of fibrotic lesions in the kidney (Zeisberg and Neilson, 2010) . Transforming growth factor-β1 (TGFβ1) and other growth factors, like epidermal growth factor (EGF) and platelet derived growth factors (PDGF), are critically involved in the fibrotic process (Bonner, 2004; Liu et al., 2012; . Those cytokines/growth factors trigger their cellular events through binding to their receptors and subsequent activation of multiple downstream signaling pathway such as signal transducer and activator of transcription 3 (STAT3), protein kinase B (AKT), and extracellular signal regulated kinase 1/2 (ERK1/2) (Qin and Han, 2010; Liu et al., 2012; Kitada et al., 2013; Liu et al., 2013; Ponnusamy et al., 2013) . It is evident that activation of epidermal growth factor receptor (EGFR) and platelet derived growth factor receptor (PDGFR) contribute to activation of renal interstitial fibroblasts and development of renal fibrosis (Bonner, 2004; LeBleu and Kalluri, 2011; Liu et al., 2011; Liu et al., 2012) .
Epigenetic modifications such as acetylation/deacetylation have also been linked to the pathogenesis of CKD Van Beneden et al., 2013; Tampe and Zeisberg, 2014) . Protein acetylation is regulated by a network of enzyme systems namely histone acetyltransferases (HATs) and histone deacetylases (HDACs). HDACs can modulate both acetylation of both histone and non-histone proteins associated with fibrogenic process such as STAT3 (Rombouts et al., 2002; Qin and Han, 2010) . Among the four classes of HDACs, Class I and II HDACs have been extensively studied for their role in tissue fibrogenesis (Pang et al., 2009; Pang et al., 2011) . It is evident This article has not been copyedited and formatted. The final version may differ from this version.
JPET Fast Forward. Published on as DOI: 10.1124 at ASPET Journals on October 18, 2017 jpet.aspetjournals.org Downloaded from JEPT #224386 6 that small molecular inhibitors acting on these two classes of HDACs were effective in attenuating fibrosis in multiple organs including kidney (Pang et al., 2009; Liu et al., 2013; Van Beneden et al., 2013) . Apart from class I and II HDACs, the role of Sirtuins (SIRTs), a Class III HDAC, has also been intensively studied in animal models of kidney diseases.
Among the seven members of SIRTs, SIRT1 is ubiquitously expressed in renal tissue, and has been shown to be implicated in renal protection under ischemic, hypoxic and calorie restricted conditions (Fan et al., 2013; Kitada et al., 2013; Dong et al., 2014) . However, the role of SIRT1 in renal fibrogenesis remains controversial even though its activity increases in the fibrotic kidney (Ponnusamy et al., 2014) . Earlier studies have indicated that activation of SIRT1 by resveratrol, a polyphenol found in red wine that is believed to be an activator of SIRT1, can alleviate renal fibrosis induced by unilateral ureteral obstruction in mice (Li et al., 2010 ). However, our recent studies showed that inhibition of SIRT1 and 2 with sirtinol attenuated renal fibrosis in the same model. In addition, specific inhibition of SIRT1 by EX527 or silencing of SIRT1 with siRNA suppressed activation of renal interstitial fibroblasts (Ponnusamy et al., 2014) .These obviously conflicting results make it difficult to explain the functionality of SIRT1 in renal fibrogenesis and raise the issue whether the antifibrotic effect of resveratrol is due to its non-specific effects. It is well documented that this compound indeed has off-target effects (Pacholec et al., 2010) . Indeed, a recent report from Ventruelli et al. (2013) showedthat resveratrol has an inhibitory effect on class I, II and IV HDACs (Venturelli et al., 2013) . In the view that blocking of class I/II HDACs can attenuate renal fibrosis (Pang et al., 2009; Liu et al., 2013) , this suggests the possibility that resveratrol may alleviate renal fibrosis through a mechanism involved in the inhibition of class I/II HDACs rather than activation of SIRT1. Therefore, additional experiments are needed to characterize the role of SIRT1 activation in regulating renal fibrosis by using more specific SIRT1 pharmacological activators. This article has not been copyedited and formatted. The final version may differ from this version. Efforts have been made to discover new molecules that are able to stimulate SIRT1 activities more specifically and potentially than resveratrol. SRT1720 is structurally unrelated to resveratrol and does not share "off-target" effects of resveratrol (Villalba and Alcain, 2012) , therefore it is a useful tool for verifying putative SIRT1-dependent effects in vivo. In this study, we investigated that the influence of SRT1720 on the progression of renal fibrosis in a murine model of renal fibrosis induced by unilateral uretheral obstruction (UUO) and on the activation of cultured renal fibroblasts.
Materials and Methods
Chemicals and Antibodies.Antibodies to fibronectin, collagen I(A2), EGFR, glyceraldehyde-3 phosphate dehydrogenase (GAPDH), and proliferating cell nuclear antigen (PCNA) were obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). All other antibodies used in this study were purchased from Cell Signaling Technology (Danvers, MA, USA). SRT1720 was purchased from EMD millipore (USA). α-smooth muscle actin (α-SMA) and all other chemicals were purchased from Sigma (St Louis, MO).
Cell Culture and Treatments.Rat renal interstitial fibroblasts (NRK-49F)were cultured in Dulbecco's modified eagle's medium with F12 (DMEM-F12) containing 5% fetal bovine serum (FBS), 0.5% penicillin and streptomycin in an atmosphere of 5% CO 2 and 95% air at 37 o C. To reduce the interference of growth factors in serum with SRT1720 activity, NRK-49F cells were grown in DMEM-F12 with 2.5% FBS for 24 hours, and SRT1720 was directly added to subconfluent NRK-49F cells and incubated for 36 hours to determine the effects of SRT1720 on renal fibroblast activation. Bar Harbor, ME, USA) as described in our previous studies (Pang et al., 2009; . Briefly, the abdominal cavity was exposed via a midline incision and the left ureter was isolated and ligated. The contralateral kidney was used as a control. To examine the effects of SRT1720 on renal fibrosis after UUO injury, SRT1720 at 200 mg/kg body weight (prepared in 50 μ l of DMSO) was intraperitoneally (i.p) administered immediately after ureteral ligation and then given daily for 4 days. The dose of SRT1720 was selected based on a previous report (Imanishi et al., 2012 Densitometry Analysis. The semiquantitativeanalysis of different proteins were carried out by using ImageJ software developed at NIH, USA. The quantification is based on the intensity (density) of band, which is calculated by area and pixel value of the band. The quantification data are given as the ratio between target protein and loading control (house keeping protein) and the ratio between phosphorylated and corresponding total protein.
Statistical Analysis.Data are presented as means ± SD and were subjected to one-way analysis of variance. Multiple means were compared using Tukey's test, and differences between two groups were determined by Student's t test. P < 0.01 was considered statistically significant.
Results
SRT1720 enhances deposition of ECM components and activation of renal fibroblasts in
the kidney after UUO injury. Progressive interstitial fibrosis is the result of excessive production of extracellular matrix (ECM) components by activated fibroblasts (Zeisberg and Neilson, 2010) . Our recent study have shown that SIRT1 and 2 activities are increased in UUO injured kidney, but its level was not affected by SRT1720 treatment (Fig. 1, C and E) . Immunoblot analysis showed that UUO injury increased the expression of SIRT1, but SRT1720 did not reduce its expression (Supplemental Fig. 1 ).
The expansion of renal interstitial fibrosis is classically manifested by an increase in the population of myofibroblasts, the phenotypically transformed fibroblasts that express α -SMA and produce ECM components (Meran and Steadman, 2011) . By immunoblot analysis, we examined the expression of fibroblast activation and proliferation markers in UUO injured kidney of mice treated with or without SRT1720. As shown in their levels were further enhanced in fibroblasts exposed to 2 μ M of SRT1720. To demonstrate that this increase is due to the activation of SIRT1 deacetylase activity, we also examined the level of Ac-H3K9. As expected, SRT1720 treatment decreased the level of Ac-H3K9 in a dose dependent manner (0.5-2 μ M). The level of Ac-H3K9 was significantly decreased (~70%) at a concentration of 1 μ M SRT1720 treatment and further decreased more than 90% at a dose of 2 μ M (Fig. 3, A and D) . However, SRT1720 treatment did not increase the level of PCNA (Fig. 3 , E and F), and cell proliferation even at the maximum concentration (2 μ M) as indicated by cell counting (Fig. 3G ) and MTT assay (Fig. 3H) .
Similarly, SRT1720 treatment did not increase PCNA level in cultured renal proximal tubular This article has not been copyedited and formatted. The final version may differ from this version. We furtherexamined the effect ofYK-3-237, another potent activator of Sirt1 (Yi et al., 2013) , on the activation of renal interstitial fibroblasts using NRK-49F cells. Our data demonstrated that exposure of cells to YK-3-237also significantly reduced expression of α -SMA and fibronectin in a dose-dependent manner, with the maximum inhibition at 10 μM.
This dose of the inhibitor completely blocked expression ofAc-H3K9, suggesting its effectiveness in the activation of Sirt1 (Supplemental 2).
Collectively,our data provide the strong evidence that SIRT1 plays a critical role in mediating activation of renal interstitial fibroblasts.
SRT1720 enhances UUO-induced phosphorylation of EGFR and PDGFRβin obstructed
kidneys. Activation of growth factor signaling pathways is involved in the regulation of fibrosis development. Our studies and those of others have shown that EGFR and PDGFRβ are two major contributors to renal fibroblast activation and renal fibrogenesis (Ludewig et al., 2000; Terzi et al., 2000; Bonner, 2004; Di Pascoli et al., 2013) . To determine whether SRT1720 exerts its profibrotic effects through activation of these two receptors, we examined the effect of this agent on the phosphorylation of EGFR at Tyr1068 (Y1068) and PDGFRβ at Tyr751(Y751). As shown in Fig. 4 , the level of phospho-EGFR was increased by ~4 fold after 4 days in the kidney with UUO injury, and SRT1720 treatment enhanced phospho-EGFR level up to 4-fold when compared to UUO injured kidney treated with the vehicle.
Interestingly, SRT1720 administration also increased phospho-EGFR levels more than 8-fold in the sham-operated kidney compared with the control kidney (Fig. 4, A and B) . In addition, UUO injury resulted in increased expression of total EGFR, however SRT1720 treatment did This article has not been copyedited and formatted. The final version may differ from this version. 13 not alter its expression levels (Fig. 4, A and C) . Similarly, SRT1720 was also effective in potentiating PDGFRβ phosphorylation in either sham-operated and UUO injured kidneys (Fig. 4, A and D) but not altering the level of total PDGFRβ (Fig. 4, A and E) . Collectively, our data suggest that SRT1720 treatment enhances phosphorylation of both EGFR and PDGFRβ in the fibrotic kidney.
SRT1720 enhances phosphorylation/activation of EGFR and PDGFRβin cultured renal
fibroblasts. To specifically demonstrate that SRT1720 induced enhancement of EGFR and PDGFRβ activation occurs in renal fibroblasts during UUO injury, we further examined the effect of SRT1720 on their phosphorylation status in cultured renal fibroblasts. Consistent with our in vivo data, exposure to SRT1720 also dose-dependently increased the phosphorylation level of EGFR and PDGFRβ in cultured NRK-49F cells (Fig. 5, A and B ). In addition, SRT1720 increased the level of total EGFR, with the maximum effect at 2 μ M, but this agent did not affect the level of total PDGFRβ (Fig. 5, A and C) . Thus, SRT1720 can enhance EGFR and PDGFRβ phosphorylation in renal fibroblasts, but with different effect on their total protein levels.
SRT1720 enhances phosphorylation of STAT3, but not ERK1/2 in UUO injured kidney
and cultured renal fibroblasts. EGFR and PDGFRβ exert their biological functions through activation of several intracellular signaling pathways including STAT3, AKT and ERK1/2 (Ludewig et al., 2000; Liu et al., 2012; Tang et al., 2013) , and these pathways are also associated with development of renal fibrosis Lan and Du, 2015) . Thus, we further examined the influence of SRT1720 on their phosphorylation in vivo and vitro. As shown in Fig. 6 , A-C, the phosphorylation levels of STAT3 (Y705) and total STAT3 were (Fig. 6 , A, D and E). Although increased levels of phosphorylated and total ERK1/2 were detected in the obstructed kidney, treatment with SRT1720 did not affect these responses (Fig. 6 , F and G).
We further examined the effect of SRT1720 on the phosphorylation and expression of STAT3, AKT, ERK1/2 in cultured renal fibroblasts. As shown in Fig. 7 , SRT1720 treatment at 1 and 2 μ M remarkably increased the phosphorylation level of STAT3 (Fig. 7, A and B) .
Similarly, SRT1720 at 2 μ M also enhanced AKT phosphorylation (Fig. 7 , A and C), however, phosphorylation of ERK1/2 was not affected by SRT1720 (Fig. 7, A and D) . In addition, SRT1720 treatment resulted in decrease of total AKT (Fig. 7 , A and C), but not total STAT3 (Fig. 7, A and B) or ERK1/2 (Fig. 7 , A and D) levels in cultured renal fibroblasts.
Collectively, these data indicate that SIRT1 activation by SRT1720 regulates phosphorylation of STAT3 and AKT, but not ERK1/2, suggesting that SRIT1 has a diverse role in regulating activation of intracellular signaling pathways.
Discussion
Sirtuin-activating compounds such as resveratrol have been widely studied for their ability to treat aging-related disorders in metabolic, cardiovascular, and neurodegenerative diseases This article has not been copyedited and formatted. The final version may differ from this version. 15 (Stunkel and Campbell, 2011; Villalba and Alcain, 2012) . However, due to the poor specify and bioavailability of resveratrol, several molecules that are structurally unrelated to resveratrol has been developed to stimulate sirtuin activities, which are more potent and specific than resveratrol. SRT1720 is a newly developed and effective SIRT1 activator that has been shown to have the potential to treat diabetes and other diseases (Dong, 2012) . In this study, we examined the pharmacological effect of SRT1720 on the development of renal fibrosis and activation of renal fibroblasts in a mouse model of UUO and cultured renal interstitial fibroblasts. Our results showed that activation of SIRT1 with SRT1720 potentiated these pathological processes. Moreover, exposure of cultured renal interstitial fibroblasts to YK-3-237, another SIRT1 activator, also promoted their activation as demonstrated by increased expression of α -smooth muscle actin and fibronectin. These results provide the strong evidence that SIRT1 plays an essentialrole in mediating renal fibrogenesis after chronic kidney injury.
Our findings are contrary to a previous report in which activation of SIRT1 was demonstrated as an anti-fibrotic mechanism in the kidney by using resveratrol (Li et al., 2010) . Currently, the molecular basis behind the striking inconsistencies generated by these two SIRT1 activators in term of fibrosis regulation remains unclear. One possible explanation is that resveratrol acts on other targets rather than on SIRT1. In this regard, it has been reported that resveratrol has a property to inhibit the activity of class I, II and IV HDACs (Venturelli et al., 2013) . As blocking class I/II HDACs with their specific inhibitors or siRNA has been shown to suppress renal fibroblast activation (Pang et al., 2009; Pang et al., 2011; Liu et al., 2013) and those class I/II HDACs inhibitors are also effective in attenuating renal fibrosis (Pang et al., 2009; Liu et al., 2013) , resveratrol induced inhibition of these enzymes may override its role as the activator of SIRT1, thereby exhibiting an anti-fibrotic This article has not been copyedited and formatted. The final version may differ from this version. and PDGFRβ is associated with the activation of renal fibroblasts, expression of pro-fibrotic factors and uncontrolled accumulation of ECM in the interstitial space LeBleu and Kalluri, 2011; Liu et al., 2011; Liu et al., 2012; Liu et al., 2013) . Class I/II HDACs have been suggested to mediate activation of several growth factor receptor signaling pathways, including EGFR and STAT3 activity in the kidney after chronic injury (Bruzzese et al., 2011; Chou et al., 2011; Liu et al., 2013) . Similar to this, inhibition of SIRT1 reduced the phosphorylation of EGFR and PDGFRβ in cultured renal fibroblasts and fibrotic kidneys (Ponnusamy et al., 2014) . All these studies provide the strong evidence that HDACs including SIRT1 can function as a positive regulator of cellular membrane receptors associated with fibrotic process. Thus, stimulation of SIRT1 by SRT1720 would result in the activation of these profibrotic signaling molecules. The mechanism by which SRT1720 enhances the phosphorylation of receptor tyrosine kinases remains unknown. One possibility is that SRT1720 induced SIRT1 activation reduces the activity of tyrosine phosphatase. In supporting this hypothesis, SIRT1 is found to suppress the expression of protein tyrosine phosphatase 1B (Sun et al., 2007; Gagarina et al., 2010) , a member of dephosphorylating protein family, which negatively regulates the activity of growth signaling molecules including EGFR and PDGFRβ (Gu et al., 2003; Ponnusamy et al., 2013) . Nevertheless, we cannot rule out the possibility that SRT1720 can also stimulate renal fibrosis through stimulation of TGF-β signaling activation as it has been reported that activation of SIRT1 promote the phosphorylation of STAT3 by inhibiting its acetylation in addition to its influence on protein tyrosine phosphatase system. On the other hand, SRT1720 mediated SIRT1 activation may regulate STAT3 through suppressing the activity/expression of suppressor of cytokine signaling (SOCS) family members such as SOCS1 and SOCS3, the negative regulators of STAT3. In fact, these two SOCS not only promote dephosphorylation but also ubiquitination and degradation of STAT family of proteins (Kile et al., 2002; Croker et al., 2008) . Therefore, SIRT1 mediated inhibition of SOCS 1/3 may abolish STAT3 degradation process, thereby increasing the stability of STAT3. As a result, both phosphorylated and total STAT3 levels are increased. A further detailed study should be carried out to unveil the mechanism of SRT1720 induced up-regulation of phosphorylated and total STAT3 level.
It is quite surprising that SRT1720 treatment reduced total AKT level in both fibrotic and sham operated kidney without affecting the phosphorylation of AKT (ser473), which results an increase in the ratio of pAKT to AKT. In general, phosphorylation of ser473 at the hydrophobic motif site is necessary for full activation of AKT molecule, and it is also the major site engaged with many physiological and pathological functions of AKT (Liao and This article has not been copyedited and formatted. The final version may differ from this version. Hung, 2010). Recent studies indicated that the AKT activity is controlled by negative feedback loop, which is triggered by hyperactivation of AKT and this hyperactivation has the capacity to regulate AKT stability and/or expression (Hart and Vogt, 2011; Wu et al., 2011) .
In supporting this, Wu et al. (2011) found that consecutive activation of AKT by ser473 phosphorylation promotes its rapid degradation by polyubiquitination dependent proteosomal pathway thereby it turns off AKT signaling . Given that SIRT1 promotes AKT phosphorylation through deacetylation (Horio, 2012; Li et al., 2013) , SRT1720 induced SIRT1 activity might stimulate sustained activation of AKT, which in turn leads to degradation of AKT and reduction of total AKT levels.
Sirtuin activity has been linked to metabolic control, cell survival, DNA repair, development, neuroprotection and healthy aging (Stunkel and Campbell, 2011; Villalba and Alcain, 2012) . Because sirtuin activation could have beneficial effects on human diseases, there is a growing interest in the discovery of small molecules able to stimulate sirtuin activity. Several small molecule activators of SIRT1 that are structurally unrelated to resveratrol have been developed. Among them, SRT1720 is one of the most effective SIRT1
activators. The role of SIRT1720 to treat insulin resistance, diabetes and other diseases has been tested in animals models and drugs similar to SRT1720 are currently in human clinical trials (Villalba and Alcain, 2012) . However, due to the fibrosis promoting effect of SIRT activators, a large dose and long-term application of them should be avoided when they are used clinically in the future.
In summary, this is the first study to demonstrate that activation of SIRT1 by 
